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Interferon Regulatory Factor 5-Dependent Immune Responses in the
Draining Lymph Node Protect against West Nile Virus Infection
Larissa B. Thackray,a Bimmi Shrestha,a Justin M. Richner,a Jonathan J. Miner,a Amelia K. Pinto,a Helen M. Lazear,a Michael Gale, Jr.,e
Michael S. Diamonda,b,c,d
Departments of Medicine,a Molecular Microbiology,b Pathology and Immunology,c and The Center for Human Immunology and Immunotherapy Programs,d Washington
University School of Medicine, Saint Louis, Missouri, USA; Department of Immunology, University of Washington School of Medicine, Seattle, Washington, USAe
ABSTRACT
Upon activation of Toll-like and RIG-I-like receptor signaling pathways, the transcription factor IRF5 translocates to the nucleus
and induces antiviral immune programs. The recent discovery of a homozygous mutation in the immunoregulatory gene gua-
nine exchange factor dedicator of cytokinesis 2 (Dock2mu/mu) in several Irf5/mouse colonies has complicated interpretation of
immune functions previously ascribed to IRF5. To define the antiviral functions of IRF5 in vivo, we infected backcrossed
Irf5/Dock2wt/wtmice (here called Irf5/mice) and independently generated CMV-Cre Irf5fl/fl mice withWest Nile virus
(WNV), a pathogenic neurotropic flavivirus. Compared to congenic wild-type animals, Irf5/ and CMV-Cre Irf5fl/fl mice were
more vulnerable toWNV infection, and this phenotype was associated with increased infection in peripheral organs, which re-
sulted in higher virus titers in the central nervous system. The loss of IRF5, however, was associated with only small differences
in the type I interferon response systemically and in the draining lymph node duringWNV infection. Instead, lower levels of
several other proinflammatory cytokines and chemokines, as well as fewer and less activated immune cells, were detected in the
draining lymph node 2 days afterWNV infection. WNV-specific antibody responses in Irf5/mice also were blunted in the
context of live or inactivated virus infection and this was associated with fewer antigen-specific memory B cells and long-lived
plasma cells. Our results with Irf5/mice establish a key role for IRF5 in shaping the early innate immune response in the
draining lymph node, which impacts the spread of virus infection, optimal B cell immunity, and disease pathogenesis.
IMPORTANCE
Although the roles of IRF3 and IRF7 in orchestrating innate and adaptive immunity after viral infection are established, the
function of the related transcription factor IRF5 remains less certain. Prior studies in Irf5/mice reported conflicting results as
to the contribution of IRF5 in regulating type I interferon and adaptive immune responses. The lack of clarity may stem from a
recently discovered homozygous loss-of-functionmutation of the immunoregulatory geneDock2 in several colonies of Irf5/
mice. Here, using a mouse model with a deficiency in IRF5 and wild-type Dock2 alleles, we investigated how IRF5modulates
West Nile virus (WNV) pathogenesis and host immune responses. Our in vivo studies indicate that IRF5 has a key role in shap-
ing the early proinflammatory cytokine response in the draining lymph node, which impacts immunity and control ofWNV in-
fection.
Acanonical model for type I IFN production after virus infec-tion is a two-step positive feedback loop that is regulated by
Interferon regulatory factor 3 (IRF3) and IRF7 (1). Detection of
viral nucleic acids by Toll-like receptors (TLRs), RIG-I-like
(RLRs) receptors, or DNA sensors induces nuclear localization of
IRF3, which in concert with NF-B and ATF-2/c-Jun stimulates
transcription, synthesis, and secretion of IFN- by infected cells.
Extracellular interferon beta (IFN-) binds to the type I IFN re-
ceptor (IFNAR) and triggers activation of the JAK-STAT signaling
pathway and induction of IFN-stimulated genes (ISGs) (2), which
inhibit viral entry, translation, replication, and assembly through
a variety of independent mechanisms (reviewed in reference 3).
While IRF3 is constitutively expressed in many tissues, IRF7 is an
ISG required for the expression of most IFN- subtypes and is
thus a key mediator of the type I IFN amplification loop (1, 4).
Noncanonical signaling pathways also induce type I IFN re-
sponses. Even with genetic ablation of IRF3 and IRF7 (Irf3/ 
Irf7/ double-knockout [DKO] cells or mice), type I IFN was
produced after infection with West Nile virus (WNV), dengue
virus, murine norovirus, or murine cytomegalovirus, albeit at re-
duced levels compared to wild-type (WT) cells and mice (5–8).
Consistentwith the sustained production of type I IFN, lethality in
Irf3/ Irf7/DKOmice infected withWNVor Chikungunya
viruswas not as rapid or complete as in Ifnar/mice (5, 9–11).Ex
vivo experiments with primary myeloid dendritic cells and mac-
rophages revealed that the IFN- response after WNV infection
was maintained in DKO cells but abrogated in the absence of
MAVS (5, 12). The transcription factors ELF4 and IRF5 both have
been implicated as participants in the MAVS-dependent induc-
tion of IFN- after WNV infection. A deficiency of ELF4 resulted
in reduced type I IFN production after WNV infection in mice
(13). ELF4 translocates into the nucleus after MAVS-dependent
activation, binds to IFN promoters, and cooperatively increases
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the binding affinity of IRF3 and IRF7 (13). Mice or cells lacking
IRF3, IRF5, and IRF7 (Irf3/  Irf5/  Irf7/ triple-knock-
out [TKO] cells or mice) had abrogated type I IFN and ISG ex-
pression in dendritic cells and serum after WNV infection, al-
though an IFN response still persisted in macrophages (14).
Activation of IRF5 in myeloid cells also induces proinflamma-
tory cytokine expression downstreamof TLR7 andMyD88 signal-
ing through a TRAF6- and IRAK1-dependent mechanism (15–
19). In an original study of immune cells from Irf5/ mice,
IFN- levels were normal after TLR stimulation although inter-
leukin-6 (IL-6), IL-12, and tumor necrosis factor alpha (TNF-)
levels were reduced (18). Subsequent experiments suggested that
IRF5 regulates type I IFN production in vivo after viral infection
(20, 21), and a lack of this function in Irf5/mice was associated
with enhanced susceptibility to infection with vesicular stomatitis
virus (VSV) or herpes simplex virus (HSV). In response to New-
castle disease virus (NDV) infection, IRF5 induced overlapping
and distinct sets of genes compared to IRF7, including the induc-
tion of type I IFN and proinflammatory cytokines (20, 22).
Two recent studies revealed the emergence of a spontaneous
genomic duplication and frameshift mutation in the guanine ex-
change factor dedicator of cytokinesis 2 (Dock2) that arose in at
least a subset of Irf5/ mouse colonies and inadvertently had
been bred to homozygosity (23, 24). This mutation complicates
interpretation of the relationship between type I IFN and IRF5
expression and activation because Dock2/ mice have indepen-
dent immune system defects, including effects on IFN induction
(25–27). After the Dock2 loss-of-function mutation was cor-
rected, plasmacytoid dendritic cells stimulated with TLR agonists
or HSV ex vivo showed small defects in IFN- production, more
substantive reductions in IFN-, and larger decreases in IL-6 and
TNF- levels (23, 24). However, pathogenesis studies or detailed
analysis of cytokine production in vivo after viral infection has not
been analyzed in these newly generated Irf5/Dock2wt/wtmice.
To better define the antiviral and immunoregulatory function
of IRF5 in vivo, we infected Irf5/Dock2wt/wt mice with WNV
in the present study. These mice were highly vulnerable to infec-
tion with WNV, with most Irf5/  Dock2wt/wt animals suc-
cumbing to disease. This increase inmortality was associated with
enhanced viral replication in peripheral tissues as well as in the
brain and spinal cord. The loss of IRF5 was associated with de-
creased levels of proinflammatory cytokines and immune cell ac-
tivation with a relatively preserved type I IFN response. Overall,
our studies indicate that IRF5 transcriptional activity has key
functions in orchestrating the early immune response in the
draining lymph node (DLN) after WNV infection.
MATERIALS AND METHODS
Viruses and cells. TheWNV strain (3000.0259) was isolated in New York
in 2000 and passaged once in C6/36 Aedes albopictus cells. Mice were
inoculated subcutaneously in the footpad with 102 PFU of WNV diluted
in Hanks balanced salt solution (HBSS) and 1% heat-inactivated fetal
bovine serum (FBS). Virus titers in tissues were analyzed by plaque assay
using Vero cells, as described previously (28).
Mice. C57BL/6J wild-type (WT) mice were commercially obtained
from Jackson Laboratories. Irf5/mice (18) originallywere a gift fromT.
Taniguchi (Tokyo, Japan) and obtained from I. Rifkin (Boston, MA) and
K. Fitzgerald (Worcester, MA) and had been backcrossed eight genera-
tions. After detection of a homozygous Dock2 mutation in this line, we
backcrossed the line for an additional five generations and selected ani-
mals that were Dock2wt/wt using PCR-based genotyping (23). Irf5fl/fl mice
(29) on a C57BL/6 background were a gift from P. Pitha (Baltimore, MD)
and crossed to congenic CMV-Cre recombinase mice (Jackson Laborato-
ries) to generate an independent gene deletion of IRF5. Deletion of the
floxed region results in a frameshift mutation that creates a premature
stop codon in exon 3 of the Irf5 gene (29). All mice were housed in a
pathogen-free mouse facility at the Washington University School of
Medicine and experiments were performed in accordance with federal
and university regulations. The protocols were approved by the Institu-
tional Animal Care and Use Committee at the Washington University
School of Medicine (assurance number A3381-01). Mice (9 to 10 weeks
old) were inoculated subcutaneously via footpad injection with 102 PFU
of WNV diluted in 50 l of HBSS supplemented with 1% heat-inacti-
vated FBS.
For immunization studies, a purified,H2O2-inactivatedWNV-Kunjin
vaccine (30) was used.WT and Irf5/mice were immunized subcutane-
ously in the footpad with H2O2-WNV-KUNV containing 10
7 PFU
equivalents/g protein that was adjuvanted with Matrix M1 (10 g/
mouse; Novavax, Inc.) in phosphate-buffered saline (PBS). Serum sam-
pleswere obtained ondays 14 and 28, andmicewere boosted on day 30. At
day 60, a final serum sample was obtained, and bone marrow and spleno-
cytes were harvested for long-lived plasma cell (LLPC) andmemory B cell
(MBC) analysis (see below).
The genotyping primers spanning the Dock2 exon duplication were
published recently (ln29.4F, 5=-GAC CTT ATG AGG TGG AAC CAC
AAC C-3=; lnR22.3.1R, 5=-GAT CCA AAG ATT CCC TAC AGC TCC
AC-3=) (24). Genotyping primers for an internal control gene (CD19) to
confirm adequacy of DNA sample preparation also have been published
(oIMR1589F, 5=-CCT CTC CCT GTC TCC TTC CT-3=; oIMR1590R,
5=-TGG TCT GAG ACA TTG ACA ATC A-3=) (24).
Measurement of viral burden. At specified time points (i.e., day 1, 2,
3, 4, 5, 6, 8, or 10) after WNV infection, serum was obtained by intracar-
diac heart puncture, followed by extensive perfusion (20 ml of PBS) and
organ recovery. Organs were weighed, homogenized using a bead-beater
apparatus, and titrated by plaque assay on Vero cells (28) or quantitative
reverse transcription-PCR (qRT-PCR), as described previously (14).
Quantification of type I IFN activity. Levels of biologically active type
I IFN were determined by using an encephalomyocarditis virus (EMCV)-
based cytopathic effect bioassay performed in murine L929 cells as de-
scribed previously (8). Serum samples were treated with citrate buffer (40
mM citric acid, 10 mM KCl, 135 mM NaCl [pH 3.0]) for 10 min and
neutralized with medium containing 50 mM HEPES (pH 8.0). The
amount of type I IFN per ml of serum was calculated from a standard
curve using IFN- (PBL InterferonSource).
Cytokine Bio-Plex assay. WT and Irf5/ mice were infected with
WNV, and at specified times blood and the draining popliteal lymph
nodes (LNs) were collected. Serum was isolated, and an LN homogenate
was prepared. Individual LNs were homogenized in 250l of PBS using a
bead-beater apparatus. The Bio-Plex Pro assay was performed according
to the manufacturer’s protocol (Bio-Rad).
Flow cytometry analysis of LN and spleen cells. Popliteal LNs or
spleens were dissected from naive orWNV-infected mice. Single-cell sus-
pensions were generated in Dulbecco modified Eagle medium (DMEM)
containing 10% FBS. After erythrocyte lysis with ACK buffer (0.15 M
NH4Cl, 10 mMKHCO3, 0.1 mMNa2EDTA [pH 7.2]), cells were counted
by hemocytometry, washed with PBS supplemented with 1% FBS, and
incubated with conjugated antibodies. The following antibodies (clone
names are indicated in parentheses) against mouse antigens were purchased
from BDBiosciences, eBioscience, or Biolegend: anti-CD3ε-Alexa Fluor 647
(145-2C11), anti-CD4-phycoerythrin (PE; RM4-5), anti-CD8-Alexa Fluor
700 (53-6.7), anti-CD11b-PE.Cy7 (M1/70), anti-CD11c-BD Horizon V450
(HL3), anti-CD19-PE.Texas Red (1D3), anti-CD69-Brilliant Violet 605
(H1.2F3), anti-NK1.1-PE (PK136), anti-Ly6G-PerCP.Cy5.5 (1A8), anti-
MHC-II-APC.Cy7 (I-A/I-E; M5/114.15.2), anti-F4/80-fluorescein isothio-
cyanate (FITC; BM8), and fixable viability dye Efluor 506. Cells were stained
in PBS with 1% FBS supplemented with Fc block (anti-CD16/32) to mini-
Thackray et al.
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mize nonspecific binding, and appropriate isotype control antibodies pur-
chased from Becton Dickinson Biosciences were used. The data were col-
lected on a LSRII flow cytometer and analyzed using FlowJo software
(Treestar, Inc.).
qRT-PCR.WTor Irf5/micewere infectedwithWNV, and draining
popliteal LNs were harvested 2 days later. Total RNA was extracted by
using an RNeasy kit (Qiagen). Fluorogenic qRT-PCR was performed us-
ing One-Step RT-PCR master mix and a 7500 Fast real-time PCR system
(Applied Biosystems) with published TaqMan primers and probes (14).
Gene induction was normalized to 18S rRNA levels.
B cell and antibody responses. The levels of WNV-specific IgM and
IgG (including IgG1, IgG2b, IgG2c, and IgG3) were determined using an
enzyme-linked immunosorbent assay (ELISA) against purified WNV E
protein, as described previously (31). Focus reduction neutralization as-
says on Vero cells were performed after mixing serial dilutions of serum
with a fixed amount (50 FFU) of WNV as previously described (32).
Enzyme-linked immunospot (ELISPOT) assays to determine the
number of antigen-specific LLPCs were performed as described previ-
ously (33). Briefly, mixed cellulose filter plates (Millipore) were coated
with 20 g of recombinant WNV E protein/ml in PBS overnight at 4°C.
The plates were washed twice with PBSwith 0.1%Tween 20, washed twice
with PBS, and blocked for 1 h at room temperature with DMEM supple-
mented with 10% FBS, penicillin-streptomycin, 10 mM HEPES, 50 M
-mercaptoethanol, and 10 mM nonessential amino acids. Bone marrow
cells from immunizedmice were depleted of erythrocytes using ACK lysis
buffer. Cells were resuspended at 2 106 cells/ml and serially diluted into
wells. After 8 h at 37°C, the plates were washed extensively and incubated
with 1 g/ml biotinylated anti-IgG (Sigma-Aldrich) and then incubated
overnight at 4°C. After washing, the wells were incubated with 1 g/ml
streptavidin conjugated to HRP diluted in PBS, 0.05% Tween 20, and 1%
FBS. The plates were washed, and spots were developed using a chromo-
gen substrate (AEC [3-amino-9 ethyl-carbazole]; Sigma-Aldrich). Spots
were enumerated using a Biospot Analyzer (Cellular Technology, Ltd.).
WNV-specific MBC frequencies were determined as described previ-
ously (33) by measuring the reactivity of supernatants to recombinant
WNV E protein by limiting dilution analysis (LDA) and ELISA. Spleno-
cyte suspensions were generated from immunized mice. Erythrocytes
were lysed (ACK lysis buffer; Invitrogen), andCD19	B cells were isolated
by positive selection using magnetic beads (Miltenyi Biotec). B cells were
resuspended in LDA medium (RPMI 1640, 10% FBS, penicillin-strepto-
mycin, 1mM sodiumpyruvate, 0.1mMnonessential amino acids, 10mM
HEPES, and 50 M -mercaptoethanol). B cells were cultured in 2-fold
serial dilutions starting at 200,000 cells per well in 96-well flat-bottom
plates on top of 20,000 3T3 transgenic feeder cells expressing BAFF and
CD40L and treated with 5 g/ml mitomycin C. Plates were incubated at
37°C and 5% humidified CO2 for 6 days. To calculate the frequency of
WNV-specificMBC that produced IgG, 96-well ELISA plates were coated
with 5 g/ml WNV E protein overnight at 4°C. The plates were washed
and blocked with PBS–0.05% Tween 20 supplemented with 2% (wt/vol)
bovine serumalbumin for 1 h at 37°C. Supernatants fromLDAplateswere
added to the ELISA plates (50l per well), and detection ofWNV-specific
antibody was performed as described for the ELISPOT assay. Positive
wells were defined aswells that scored 2-fold over themean optical density
of negative-control wells (wells containing feeder cells alone). Superna-
tant from cultured naive splenocytes did not score positive.
Cellular immune responses.WTand Irf5/mice were infected sub-
cutaneously in the footpad with 102 PFU of WNV and, at 8 days after
infection, the spleens and brains were harvested after extensive cardiac
perfusion with PBS. Splenocytes were dispersed into single cell suspen-
sions with a cell strainer. Brains were minced and digested with 0.05%
collagenaseD, 0.1g/ml trypsin inhibitor TLCK, and 10g/mlDNase I in
HBSS supplemented with 10 mM HEPES (pH 7.4; Life Technologies).
Cells were dispersed into single cell suspensions with a cell strainer and
pelleted through a 30% Percoll cushion for 30 min (1,200  g at 4°C).
Intracellular IFN-
 staining was performed after ex vivo restimulation
with a Db-restricted NS4B immunodominant peptide using 1 M pep-
tide and 5 g/ml brefeldin A (Sigma) as described previously (34).
Cells were stained with the following antibodies and processed on an
LSR II flow cytometer (Becton Dickinson): CD3 (Becton Dickinson, clone
145-2C11), CD4 (Biolegend, clone RM4-5), CD8 (Biolegend, clone
YT5156.7.7), CD45 (Biolegend, clone 30-F11), CD11b (Becton Dickinson,
clone M1/70), CD11c (Becton Dickinson, clone HL3) MHC-II (Biolegend,
cloneM5/114.15.2),CD43 (Biolegend, clone IM7), and IFN-
 (BectonDick-
inson, cloneXMG1.2). Flowcytometrydatawere analyzedusingFlowJo soft-
ware (Treestar).
Data analysis. All data were analyzed using Prism software (Graph-
Pad6, San Diego, CA). Kaplan-Meier survival curves were analyzed by the
log-rank test. Differences in viral burden, cytokine levels, and cell num-
bers were analyzed by the Mann-Whitney test.
RESULTS
Susceptibility of Irf5-deficient mice to WNV infection. Given
that prior viral pathogenesis studies may have used Irf5/ mice
containing a mutation in the Dock2 gene, we confirmed that our
backcrossed Irf5/ strain had the WT Dock2 allele (Fig. 1A). To
determine whether IRF5was required for restrictingWNVpatho-
genesis in vivo, we infected 9- to 10-week-old WT and Irf5/ 
Dock2wt/wt (here called Irf5/) mice with 102 PFU ofWNV (New
York 2000 strain) by subcutaneous inoculation and monitored
survival over time. Irf5/ mice exhibited enhanced mortality
(81% versus 22%, P 0.0001, Fig. 1B) and reduced average sur-
vival time (mean time to death: 10.5 and 12.2 days for Irf5/ and
WT mice, respectively, P 0.01) compared to WT mice.
To begin to determine the basis for the increased lethality
in Irf5/ mice after WNV infection, we measured viral loads in
tissues at different time points. An absence of IRF5 resulted in
enhanced viremia (9- to 10-fold at days 2 and 4 after infection,P
0.05; Fig. 1C) and increasedWNV infection in the spleen (31-fold
at day 4, P  0.01; Fig. 1D). A small effect was observed in the
kidney at day 4, since 5 of 11 Irf5/mice had measurable infec-
tious WNV compared to 0 of 10 WT mice (Fig. 1E).
Higher levels of WNV infection also were observed in central
nervous systems (CNS) of Irf5/mice compared toWT controls.
At day 4 after infection, 4 of 11 Irf5/mice had measurable viral
loads in the brain compared to 0 of 7 WT mice (Fig. 1F). Analo-
gously, 5 of 10 Irf5/mice had detectableWNV in the spinal cord
at day 6 compared to 0 of 10 WT mice (Fig. 1G). This pattern
resulted in increased titers at later times in the brain (22- to 145-
fold increase at days 6, 8, and 10, P  0.01) and spinal cord (38-
fold at day 10, P 0.01) of Irf5/mice. At day 9 after infection,
higher levels of WNV were detected in several different regions of
the brain, including the cerebellum, cerebral cortex, brain stem,
white matter, and olfactory bulb (Fig. 1J to N, P 0.05).
To corroborate these results, we crossed Irf5fl/fl mice (29) to a
congenic CMV-Cre recombinase strain to generate an indepen-
dent line with a targeted deletion of IRF5. Analogous to the data
obtained with Irf5/ mice, 9-week-old CMV-Cre Irf5fl/fl mice
succumbed to WNV infection at a greater rate than age-matched
control Cre-negative Irf5fl/fl mice (89% versus 25%, P  0.002,
Fig. 1H) and exhibited a higher viremia (8-fold at day 4 after
infection, P 0.04; Fig. 1I).
Because previous studies showed antiviral effects of the TLR
and RLR signaling pathways in resident cells of the CNS (12, 35–
37), we hypothesized that part of the enhanced WNV infection
phenotype in Irf5/mice could be explained by an IRF5-depen-
dent restriction of replication in resident neuronal cells or micro-
IRF5 Restricts West Nile Virus Pathogenesis
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FIG 1 Survival and viral burden inWT and Irf5/mice after peripheral inoculation of WNV. (A) Dock2 gene PCR results from genotyping of WT, Irf5/
Dock2mu/mu, and Irf5/Dock2wt/wtmice with primers amplifying the region flanking the duplication. A 305-bp amplicon that spans the genomic duplication
of Dock2mu/mu is observed only in the parent Irf5/mice prior to backcrossing. It is not amplified in the new Irf5/  Dock2wt/wt mice. Note, the other sized
bands are nonspecific amplification products. (B) Irf5/Dock2wt/wt (herein referred to as Irf5/) mice were infected with 102 PFU of WNV in the footpad.
Survival was monitored for 30 days: n  31 WT and 45 Irf5/ mice from at least three independent experiments. The difference was statistically different
(P 0.0001), as judged by the log-rank test. (C to G) The viral burdens after WNV infection of WT and Irf5/ mice were measured by plaque assay in
samples from serum (C), spleen (D), kidney (E), brain (F), and spinal cord (G). A scatter plot of data is shown with each individual point
Thackray et al.
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glia. To test this,WT and Irf5/mice were infected with 101 PFU
ofWNV directly into the brain via an intracranial route, and viral
burden in the cerebral cortex, white matter, brain stem, cerebel-
lum, and spinal cord was measured on days 2, 4, and 6 after infec-
tion. In contrast to the increased virus titers observed in the CNS
of Irf5/ mice after peripheral inoculation, we observed no sig-
nificant differences in infection between WT and Irf5/ mice
following intracranial injection (Fig. 2A to E, P  0.05). These
data show that IRF5 is not required to restrict WNV replication
directly in the CNS. More likely, the increased WNV titers in the
CNS after subcutaneous inoculation reflect the enhanced infec-
tion in peripheral organs, which results in dissemination to the
CNS prior to evolution of a protective adaptive immune response.
Effect of IRF5 on innate immune responses. Since IRF5 has
been reported to be required for an optimal type I IFN response in
vivo in the context of VSV, HSV, and NDV infections (20, 21), we
assessed its impact on the systemic levels of type I IFN after WNV
infection (Fig. 3A). However, we observed no significant differ-
ence in type I IFN levels in the serum of Irf5/ mice using a
sensitive EMCV-based bioassay in L929 cells at days 1, 2, or 4 after
infection. A small, yet statistically significant decrease in type I IFN
levels was observed in the serum of Irf5/ mice at day 3 after
infection.
We assessed the role of IRF5 on systemic production of other
cytokines and chemokines at 1, 2, or 4 days after WNV infection
(Fig. 3B to G). Notably, serum levels of IL-6, IL-10, IL-12p40,
macrophage inflammatory protein 1 (MIP-1; CCL3), MIP-1
(CCL4), and macrophage chemoattractant protein 1 (MCP-1;
CCL2) were lower in serum within the first 2 days of WNV infec-
tion in Irf5/ compared to WT mice. By day 4, however, differ-
ences in these cytokine and chemokine levels in serumwere largely
absent, indicating that IRF5-independent pathways could com-
pensate for their production. In comparison, levels of other in-
flammatory cytokines and chemokines (IFN-
, TNF-, IL-1,
and RANTES [CCL5]) were similar inWT and Irf5/mice (data
not shown). Overall, these results consistently show small defects
in the early serum inflammatory cytokine and chemokine re-
sponse ofWNV-infected Irf5/mice and extend results observed
previously with VSV, HSV, or NDV infection (20, 21).
Because the differences in serum levels of proinflammatory
representing a single animal. The bars indicatemean values andwere obtained from 7 to 11mice per time point. The dashed lines represent the limit of sensitivity
of the assay. Asterisks indicate statistical significance (*, P 0.05; **, P 0.01; ***, P 0.001), as judged by theMann-Whitney test. (H and I) CMV-Cre Irf5fl/fl
and control Irf5fl/fl (Cre-negative) mice were infected with 102 PFU ofWNV in the footpad. (H) Survival was monitored for 30 days: n 9 CMV-Cre Irf5fl/fl and
12 Irf5fl/fl mice from at least three independent experiments. The difference was statistically different (P 0.002), as judged by a log-rank test. (I) Viremia was
assessed by qRT-PCR at day 4 after WNV infection in CMV-Cre Irf5fl/fl and control Irf5fl/fl (Cre-negative) mice and expressed as focus-forming unit (FFU)
equivalents after comparison to a standard curve. The bars indicate mean values and were obtained from nine mice per group. The difference was statistically
significant (*, P 0.05), as judged by theMann-Whitney test. (J to N) Viral burdens in the cerebral cortex (I), cortical white matter (J), brain stem (K), olfactory
bulb (L) and cerebellum (M) in the brains ofWT and Irf5/mice on day 9 after subcutaneousWNV infection. The samples (n 7) were analyzed as described
in panels D to H.
FIG 2 Viral replication in CNS tissues of WT and Irf5/mice after intracranial infection. (A to F) Mice were infected with 101 PFU of WNV by intracranial
injection. Viral replication was measured in the cerebral cortex (A), white matter (B), brain stem (C), olfactory bulb (D), cerebellum (E), and spinal cord (F) by
plaque assay from 2 to 6 days after infection. A scatter plot of the data is shown, with each individual point representing a single animal. The bars indicate mean
values and were obtained from six mice per time point. The dashed lines represent the limit of sensitivity of the assay. None of the differences betweenWT and
Irf5/mice were statistically significant, as judged by the Mann-Whitney test.
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cytokines between WT and Irf5/ mice occurred early after in-
fection, we speculated this might reflect events occurring in the
draining popliteal LN (DLN), an initial site of WNV replication
and innate immune response after subcutaneous footpad inocu-
lation (38). We first compared levels of viral RNA in the DLN in
WT and Irf5/mice. Notably, at day 2 after infection, no differ-
ence in WNV infection was observed in the two groups of mice
(P 0.7, Fig. 4A). We next measured the levels of cytokines and
chemokines in homogenates prepared from DLN of WNV-in-
fected WT and Irf5/ mice. The levels of 11 different cytokines
and chemokineswere consistently lower inWNV-infected Irf5/
mice compared to WT mice (Fig. 4B to L). In comparison, the
mRNA levels of IFN, IFN, and two ISGs (Rsad2 andOas1) were
minimally different in DLN samples from WT and Irf5/ mice
(Fig. 4M).
While measuring cytokine and chemokine levels in DLN
homogenates, we noticed the DLN from WNV-infected Irf5/
mice were smaller in size in comparison to theirWT counterparts
(data not shown). We explored this by assessing whether a defi-
ciency of IRF5 affected the number and activation state of im-
mune cell subsets. In the popliteal LN of Irf5/ naive mice, we
measured 1.5- to 4-fold fewer cells in several leukocyte subsets,
with the differences in NK cells and macrophages attaining statis-
tical significance (Table 1). By day 2 after WNV infection, we
observed 2- to 3-fold fewer B cells, CD4	T cells, CD8	T cells, NK
cells, F4/80	macrophages, andCD11c	 dendritic cells (Fig. 5A to
F, P 0.05) in the DLN ofWNV-infected Irf5/mice compared
to WT mice. No difference in the numbers of Ly6G	 neutrophils
was detected in the DLN at this time point (data not shown).
Moreover, B cells, CD4	 T cells, and CD8	 T cells from Irf5/
mice expressed the activation marker CD69 on their surface at a
lower frequency (P  0.001, Fig. 5G to I), and Irf5/ macro-
phages expressed lower level of class II major histocompatibility
complex (MHC) antigen (P 0.001, Fig. 5K) than did cells from
WT mice. Because of the differences in cellularity of the LNs in
Irf5/ mice, we performed a similar analysis of splenocyte sub-
sets in naive andWNV-infected animals. In contrast to the differ-
ences observed in the LN, in the spleen we did not detect a differ-
ence in the number B cells, CD4	 T cells, CD8	 T cells, NK cells,
dendritic cells, or granulocytes inWTand Irf5/mice at baseline or
2 days after WNV infection (Tables 1 and 2). Collectively, these ex-
periments suggest that IRF5 has a key role in shaping the early innate
cellular immune response in the DLN after subcutaneous infection
withWNV.
Effect of IRF5 on adaptive cellular immune responses. Prior
studies revealed that an optimal T cell response to WNV requires
MAVS signaling (12) and that IRF5-dependent transcription in
dendritic cells is regulated in part by MAVS-dependent signaling
events (14). Given these findings and our current results showing
that Irf5/ mice had lower levels of proinflammatory cytokines
in the DLN and higher levels of WNV infection in organs that are
cleared by effector T cells (39–42), we evaluatedwhether defects in
cellular immune responses in peripheral tissues or the brain in
FIG 3 Systemic cytokine and chemokine responses afterWNV infection ofWT and Irf5/mice. Mice were infected with 102 PFU ofWNV in the footpad, and
serumwas harvested at days 1, 2, 3, or 4 after infection. (A) The type I IFN activity in serum ofWT and Irf5/mice wasmeasured by an EMCV cytopathic effect
bioassay. (B to G) Cytokine and chemokine levels in the sera of WNV-infected WT and Irf5/mice were measured by Bio-Plex assay. The data are presented
as scatter plots from 6 to 10 mice per group. Bars represent the means, and dotted lines indicate the limit of sensitivity of each assay. Asterisks indicate statistical
significance (*, P 0.05; **, P 0.01; ***, P 0.001), as judged by the Mann-Whitney test.
Thackray et al.




ctober 1, 2014 by W






Irf5/ mice contributed to the susceptibility phenotype after
WNV infection.
We initially harvested splenocytes from WT and Irf5/mice
at 6 days after WNV infection, a relatively early time point in the
evolution of the cellular response, and performed immunopheno-
typing analysis. Cells were stained with Db-NS4B peptide tetram-
ers to establish antigen specificity and antibodies to granzyme B to
monitor effector function (Fig. 6A to C). No significant difference
in the percentage of number of NS4B-tetramer positive cells ex-
pressing Granzyme B inWNV-infectedWT and Irf5/mice was
detected at day 6 (P 0.1).We also analyzed the cellular response
in the spleen at a later time, day 8 after infection. Cells were stained
with antibodies to detect T cells (CD3, CD4, and CD8) and the
production of effector molecules (IFN-
) after WNV peptide re-
stimulation and to detect Db-NS4B peptide tetramers. Again, we
observed no significant differences in the percentage or total num-
ber of CD4	 or CD8	 T cells (Fig. 6D and E, P 0.4) or antigen-
specific tetramer-positive CD8	T cells (Fig. 6F andG, P 0.7) in
the spleens of WNV-infected WT and Irf5/ mice. Consistent
with this, after ex vivo peptide restimulation, we detected no dif-
ference in the percentages or numbers of CD8	 T cells producing
IFN-
 (Fig. 6H and I, P 0.5) or TNF- (data not shown).
Although T cell responses were intact in the spleens from
Irf5/mice, it remained possible that the viral burden phenotype
in the CNS was due, in part, to impaired immune cell trafficking
across the blood-brain barrier or altered function of cells within
the CNS. To address this, we analyzed immune cell accumulation
in the brain at day 8 after WNV infection. We observed no differ-
ence in the percentages or numbers of NS4B-specific CD8	T cells
(Fig. 7A and B, P  0.2) or IFN-
-producing CD8	 T cells after
peptide restimulation (Fig. 7C and D, P 0.2) in the brain. Anal-
ogously, the percentages or numbers of CD11b	CD45lomicroglia
or infiltrating CD11b	CD45hi macrophages (Fig. 7E and F, P 
0.2) in the brains of WNV-infected WT and Irf5/ mice were
similar. Thus, the increased WNV titers observed in the CNS of
Irf5/ mice were not due to major defects in the generation or
localization of antigen-specific T cells or other inflammatory cells.
Effect of IRF5 on humoral immune responses. Prior studies
have suggested that IRF5 regulates Ikaros expression in B cells to
generate an optimal class-switched antibody response to T-de-
FIG 4 Cytokine and chemokine responses in the draining popliteal LNs after WNV infection of WT and Irf5/mice. Mice were infected bilaterally with 102
PFU of WNV in the footpad, and LNs were harvested at day 2 after infection. (A) Levels of viral infection in LN homogenates as measured by qRT-PCR. The
differences were not statistically different as measured by the Mann-Whitney test. (B to L) Cytokine and chemokine levels in LN of WNV-infected WT and
Irf5/mice weremeasured by a Bio-Plex assay. The data are presented as scatter plots from 6 to 11 independentmeasurements, reflecting a total of 12 to 22 LNs
over three or four independent experiments for each genotype. Bars represent the mean and dotted lines indicate the limit of sensitivity of each assay. (M)
Expression of the indicated IFNs and ISG in the DLN was measured from total RNA 2 days after WNV infection of WT and Irf5/mice by qRT-PCR. Gene
expression was compared to levels of 18S rRNA in the sample and displayed as the CT value. The data represent the averages from eight samples from two
independent experiments. In this figure, asterisks indicate statistical significance (*,P 0.05; **,P 0.01; ****,P 0.0001) as judged by theMann-Whitney test.
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pendent and -independent antigens (29) and that an absence of
IRF5 alters B cell maturation (43), which prevents the develop-
ment of antinuclear antibodies in a murine model of systemic
lupus erythematosis (SLE) induced by pristine injection (44).
Given that recent studies suggested that at least some of the cell-
intrinsic B cell defects originally described could be due to the
adventitious homozygous mutation of Dock2 that was present in
many Irf5/ mouse colonies (23, 24), we analyzed humoral re-
sponses to WNV infection in our Irf5/mice, which have a WT
Dock2 allele. This analysis also was important because the B cell
response to WNV is critical for controlling viremia and dissemi-
nation into the CNS (28, 32, 45).
To assess the effect of IRF5 on early WNV-specific antibody
responses, we analyzed serum from Irf5/ andWTmice 4 and 8
days after infection for binding to WNV E protein. At day 4, we
observed a small decrease in themagnitude of the IgM response in
Irf5/ mice (2-fold, P  0.01, Fig. 8A). By day 8, no difference
was observed in the IgM response (Fig. 8B). At day 8, we also
observed slightly lower levels (2-fold, P 0.01, Fig. 8C) ofWNV-
specific IgG in Irf5/ mice. However, this difference was subtle
and did not impact the neutralizing capacity of serum (Fig. 8D).
One caveat to this analysis of the humoral response was that we
observed 2-fold lower antibody titers in the setting of substantially
increased viral replication, especially in the spleen (see Fig. 1D). In
prior studies with mice deficient in IFN-
 (46), increased replica-
tion in peripheral organs was associated with higher antibody re-
sponses possibly secondary to the increased amount of viral anti-
gen present. Thus, the higher level of antigen associated with
enhanced infection of Irf5/mice couldmask defects in the evo-
lution of the humoral response. Given this possibility, and the
prior studies suggesting a B cell intrinsic effect of IRF5 (29), we
assessed anti-WNV B cell responses in WT and Irf5/mice after
immunization with a nonreplicating H2O2-inactivated vaccine
candidate (30). Mice were immunized with adjuvanted H2O2-in-
activated WNV-Kunjin strain and boosted at day 30. One month
later, the spleens and bone marrow were harvested for analysis of
WNV-specific MBCs and long-lived plasma cells (LLPCs) by lim-
iting dilution and ELISPOT analyses (33), respectively. Consistent
with a role for IRF5 in optimal B cell responses (29), Irf5/mice
had fewer WNV-specific MBCs and LLPCs at day 60 after initial
vaccination (Fig. 8E and F). Lower titers of WNV-specific anti-
bodies in serum also were observed in immunized Irf5/mice at
day 60, 1 month after boosting (Fig. 8G). As reported previously
(29), part of this defect reflected isotype skewing away from virus-
specific antibodies of the IgG2c subtype (Fig. 8H). Similar to that
seen with infectious WNV, the differences in serum and cellular
antibody responses with nonreplicating inactivated virus between
WT and Irf5/ mice were reproducible yet relatively small. Al-
though IRF5 contributes to an optimal humoral response, it is not
required for its generation.
DISCUSSION
Although the roles of IRF3 and IRF7 in regulating IFN-dependent
and IFN-independent antiviral responses are well established, the
significance of the transcription factor IRF5 in this response has
remained less certain, in part due to variation in results obtained
from different groups with Irf5/ mice. One explanation for
these conflicting results was the recent discovery of a spontaneous
genomic duplication and frameshift mutation in the guanine ex-
change factor Dock2 that had arisen spontaneously in several col-
onies of Irf5/mice and inadvertently been bred to homozygos-
ity (23, 24). Because Dock2-deficient mice have independent
immune system defects, including effects on type I IFN induction
(25–27), the relationship between IRF5 expression, type I IFN
production, and viral pathogenesis required reassessment. In
more recent studies, we used Irf3/  Irf7/ DKO mice and
Irf3/ Irf5/ Irf7/TKOmice to assess whether IRF5was
a possible source of the residual induction of IFN- and ISGs in
dendritic cells (14). These experiments suggested that, in the ab-
sence of the transcription factors IRF3 and IRF7, IRF5was respon-
sible for mediating the type I IFN and ISG response after WNV
infection. However, these studies did not explore the nonredun-
dant functions of IRF5 and their effects on restriction of virus
infection.
Here, using Irf5/mice withWTDock2 alleles, we established
a protective role for IRF5 in the context of WNV infection. These
results were corroborated with CMV-Cre Irf5fl/fl mice, an inde-
pendently generated mouse line with a targeted deletion of IRF5.
An absence of IRF5 in vivo resulted in increased lethality and
higher viral loads in the CNS compared to WT mice. Detailed
virological and immunological analyses revealed that IRF5 con-
tributed to the control of WNV at the earliest stages, since infec-
tion was increased in the blood and the spleen within a few days of
inoculation, which ultimately resulted in enhanced replication in
the brain and spinal cord. IRF5 had a subordinate role in the
induction of type I IFN since relatively minor defects in the serum
or DLN levels were detected in WNV-infected Irf5/ mice. In
comparison, mice lacking IRF5 showed blunted production of
proinflammatory cytokines and chemokines at early time points,
which was associated with fewer immune cells being recruited to
the DLN. Vaccination and infection studies in Irf5/ mice also
TABLE 1 Number of cells in the naive popliteal LNs and spleens of WT
and Irf5/micea
Cell type
Mean no. of cells SD
PWT mice Irf5/mice
Lymph node
CD19	 B cells 2.9 105 8.9 104 7.5 104 3.7 104 0.07
CD4	 T cells 1.6 105 2.7 104 8.1 104 4.2 104 0.13
CD8	 T cells 1.3 105 2.3 104 5.7 104 2.8 104 0.11
NK1.1	 NK cells 4.8 103 1.0 103 1.2 103 3.3 102 0.04
CD11b	 F4/80	
macrophages
1.9 103 9.9 102 3.2 102 1.7 102 0.02
CD11c	 DCs 1.1 103 8.2 102 1.9 102 1.4 102 0.10
Lys6G	
granulocytes
9.0 102 3.6 102 2.6 102 1.1 102 0.11
Spleen
CD19	 B cells 2.6 107 3.0 106 2.7 107 3.0 106 0.68
CD4	 T cells 9.7 106 8.9 105 1.1 107 1.1 106 0.50
CD8	 T cells 5.9 106 8.6 105 6.7 106 7.0 105 0.52
NK1.1	 NK cells 2.1 106 2.6 105 1.8 106 2.1 105 0.57
CD11c	 DCs 5.3 104 6.8 103 7.7 104 1.0 104 0.14
Lys6G	
granulocytes
5.6 105 1.0 105 1.5 106 5.0 105 0.14
a Popliteal lymph node cells and splenocytes were collected from uninfected WT and
Irf5/mice. Cells were phenotyped (see Materials and Methods) and processed by
flow cytometry. The results are the averages from three to five mice per group. The
groups were compared, and the indicated P values of0.05 (Mann-Whitney test)
reached statistical significance. DCs, dendritic cells.
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revealed defects in the generation of an optimal acute andmemory
B cell response, although the antigen-specific CD8	 T cell re-
sponse remained preserved. Collectively, our results suggest that
the nonredundant role of IRF5 is primarily immunomodulatory,
since its transcriptional activity shapes the magnitude, composi-
tion, and activation state of cellular infiltrates in lymphoid tissues.
This activity modulates the early antiviral response and the tran-
sition to adaptive immunity, especially in the B cell compartment.
Our experiments suggest that in vivo, IRF5 does not have a
major nonredundant role in regulating systemic type I IFN pro-
duction, at least after WNV infection. These data are consistent
with the original characterization of Irf5/ mice (18) in which
defects in proinflammatory cytokine production but not IFN-
production were observed after the treatment of dendritic cells or
animals with TLR agonists. These results vary with those reported
after infection with other viruses, which showed reduced levels of
IFN- and IFN- in serum of infected Irf5/ mice (20, 21), al-
though some of the differences were small and did not attain sta-
tistical significance (20). While the basis for the discrepancy in
nonredundant effects of IRF5 on the systemic type I IFN response
warrants further analysis, there are at least two possible explana-
tions. First, cell-type-specific effects of IRF5 in the context of in-
fection by different viruses could impact the induction of type I
IFN. In the context of NDV infection, an absence of IRF5 in cul-
tured dendritic cells but not peritoneal macrophages was associ-
ated with reduced levels of type I IFN in the supernatant (20).
Irf5/ plasmacytoid dendritic cells obtained directly from mice
FIG 5 Leukocyte infiltration and activation in popliteal LNs ofWNV-infectedWT and Irf5/mice.WT and Irf5/mice were infected with 102 PFU ofWNV
in the footpad. Two days later, the draining popliteal LNs were harvested, and the cells were counted and stained with monoclonal antibodies to detect specific
cell populations, including CD19	 B cells (A), CD4	 T cells (B), CD8	 T cells (C), NK1.1	 NK cells (D), CD11b	 F4/80	 macrophages (E), and CD11c	
dendritic cells (F). B cells (G) and T cells (H and I) were costained with MAbs to CD69 and macrophages were stained with MAbs to class II MHC (MHC II) (J)
to establish activation state. The results are the pooled from two independent experiments with a total of 9 to 10 mice per group, and bars indicate the standard
errors of the mean. Asterisks indicate statistical significance as judged by the Mann-Whitney test (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P 0.0001).
TABLE 2 Number of immune cells in the spleens of WT and Irf5/
mice at day 2 after WNV infectiona
Cell type
Mean no. of cells SD
PWT mice Irf5/mice
CD19	 B cells 2.2 107 2.0 106 2.3 107 2.1 1046 0.67
CD4	 T cells 9.2 106 1.0 106 1.1 107 7.8 105 0.25
CD8	 T cells 5.8 106	 5.7 105 6.4 106 2.9 105 0.20
NK1.1	 NK cells 1.7 106 2.1 105 1.8 106 2.1 105 0.91
CD11c	 DCs 4.2 104 7.5 103 6.5 104 1.0 104 0.07
Lys6G	 granulocytes 6.2 105 1.7 105 1.0 106 4.8 105 0.43
a Splenocytes were collected from WT and Irf5/mice 2 days after WNV infection.
Cells were phenotyped (see Materials and Methods) and processed by flow cytometry.
The results are the averages from five to seven mice per group. None of the differences
between groups attained statistical significance (P 0.05). DCs, dendritic cells.
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produced less IFN- and IFN- in response to TLR4 and TLR9
agonists (24, 47, 48) or myxoma virus (49). Analogous cytokine
induction studies with WNV have shown greater type I IFN pro-
duction from conventional myeloid compared to plasmacytoid
dendritic cells (50). Alternatively, some of the earlier studies may
have used mice carrying the Dock2 mutation, which indepen-
dently affects migration or activity of IFN-producing immune
cells (26, 27).
We did observe a role for IRF5 in regulating expression of
proinflammatory cytokine and chemokine responses, especially at
early times afterWNV infection in serumand theDLN.This result
agrees with studies in Irf5/mice that used other inflammatory
agonists or viruses as stimuli (18, 20, 21, 23). Nonetheless, the
signaling pathway that induces these proinflammatory molecules
remains uncertain. Although IRF5-dependent cytokine induction
after TLR agonist stimulation occurs via MyD88- and/or TRIF-
dependent pathways (18, 51), after viral infection it also depends
on RLR- andMAVS-dependent signals (14, 52). Indeed, IRF5 has
FIG 6 T cell responses in the spleen afterWNV infection. WT and Irf5/mice were infected with 102 PFU ofWNV in the footpad. Splenocytes were harvested
and analyzed by flow cytometry at day 6 (A to C) or 8 (D to I) after infection. The percentages and numbers of NS4B tetramer	CD8	T cells (A and F), granzyme
B	 CD8	 T cells (B), total CD8	 T cells (D), total CD4	 T cells (E), or IFN-
-expressing CD8	 T cells after restimulation with an immunodominant NS4B
peptide (H) are shown. Symbols represent individual mice. (C, G, and I) Representative flow cytometry plots of NS4B tetramer	 (C and G), granzyme B	 (C),
and IFN-
	CD8	 (I) T cells fromWT and Irf5/mice at days 6 or 8 after infection. Numbers indicate the percentage of cells in each quadrant. The results are
pooled from two independent experiments with a total of 5 to 11 mice per group depending on the experiment. None of the comparisons were statistically
different, as judged by the Mann-Whitney test.
FIG 7 Immune cell responses in the brain afterWNV infection.WT and Irf5/mice were infected with 102 PFU ofWNV in the footpad. Brain leukocytes were
harvested and analyzed by flow cytometry at 8 days after infection. Percentages and numbers ofNS4B tetramer	CD8	T cells (A), IFN-
 expressingCD8	T cells
after restimulation with an immunodominant NS4B peptide (C), and microglia (CD11b	CD45lo) and macrophages (CD11b	CD45hi) (E) are shown. Symbols
represent individual mice. (B, D, and F) Representative flow cytometry plots of NS4B tetramer	 (B), IFN-
	CD8	 T cells (D), andmicroglia/macrophages (F)
from the brains of infected WT and Irf5/mice. Numbers indicate the percentage of cells in each quadrant. The results are the pooled from two independent
experiments, with a total of 11 mice per group. None of the differences were statistically significant, as judged by the Mann-Whitney test.
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been shown to interact in a complex with RIG-I and MAVS via
coimmunoprecipitation and immunoblotting experiments (14,
21, 53). Under certain circumstances, RLR signaling can antago-
nize IRF5-dependent cytokine production as activated IRF3 can
bind dominantly, relative to IRF5, to the Il12b gene promoter and
interfere with the TLR-induced assembly of a transcription-factor
complex (54). As an additional level of regulation, histone
deacetylases and acetyltransferases associate directly with IRF5
and modulate its transcriptional activity (55). Further studies in
primary cells are needed to define the mechanistic intermediates
that link IRF5 activation and signaling to cytokine induction after
WNV infection.
Among the most significant phenotypes observed was the im-
pact of IRF5 on leukocyte numbers in the DLN before and after
WNV infection. This unexpected phenotype was not due to dif-
ferences in virus trafficking or local replication because WNV
titers were similar between WT and Irf5/mice within 2 days of
infection. Rather, our data suggest that both homeostatically and
downstream of virus infection and pathogen detection pathways,
IRF5 regulates expression of cytokines and chemokines that shape
cellular trafficking into the DLN and activation of key cell types
once they enter. In the absence of IRF5, fewer T cells, B cells, NK
cells, macrophages, and dendritic cells were present in the DLN at
day 2 after infection, and several lymphocyte subsets expressed
smaller amounts of the activation marker CD69. Given that we
observed no difference inWNV replication in dendritic cells from
WT and Irf5/ mice (14) or in neurons after intracranial infec-
tion of WT and Irf5/mice, our data are most consistent with a
cell-extrinsic indirect antiviral function of IRF5 that reflects its
immunomodulatory activity. Proinflammatory and leukocyte re-
FIG 8 B cell responses to live and inactivated WNV inWT and Irf5/mice. (A to C) Serum was obtained fromWNV-infected WT and Irf5/mice, and the
IgM levels at days 4 (A) and 8 (B) or the IgG levels at day 8 (C) after infection were measured by ELISA for reactivity with the WNV E protein. (D) Neutralizing
antibody titers were determined by a focus-reduction assay from serum at day 8. The results are shown as a scatter plot and represent samples from seven to eight
mice per group. The data are plotted as the reciprocal log10 titer, and dotted lines indicate the limit of sensitivity of the ELISA. (E to H) B cell immune responses
to inactivated WNV-Kunjin vaccine. WT and Irf5/ mice (n  10 to 15 from two to three independent experiments) were immunized with adjuvanted
WNV-Kunjin vaccine at day 0 and boosted at day 30. After vaccination, serum was obtained (days 14, 28, and 60), and splenic MBCs and bone marrow LLPCs
(day 60) were harvested. (E) WNV-specific MBCs were determined by limiting dilution assay 6 days after polyclonal stimulation, as described in Materials and
Methods. (F)WNV-specific LLPCs were determined by ELISPOT analysis. (G) Total Anti-WNV E IgG titers were determined from serum at the indicated days
by ELISA. (H) Isotype analysis ofWNV-specificMAbs was determined by ELISA on serum 28 days after immunization. Asterisks indicate statistical significance
(*, P 0.05; **, P 0.01), as judged by the Mann-Whitney test.
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cruitment functions of IRF5 in the DLN have implications for its
linkage to SLE, which can feature upregulated expression of IRF5
(56, 57), and for the metastatic potential of tumors where IRF5
expression is downregulated (58, 59).
Part of the enhanced vulnerability of Irf5/ mice to WNV
infection also may be associated with defects in B cell responses.
Despite the increase in viral infection and antigen in peripheral
tissues, we observed blunted IgM and IgG responses at early time
points. This could impact WNV pathogenesis, since the early hu-
moral response is critical for controlling viremia. Even small dif-
ferences in WNV-specific IgM levels at early times after infection
affect viral dissemination to the brain and clinical outcome (28,
32). Because of the possible confounding influence of enhanced
WNV infection and antigen burden on B cell responses in Irf5/
mice, we also performed immunization studies with a H2O2-inac-
tivated nonreplicating WNV-Kunjin virus strain (30). In these
experiments, we observed defects in Irf5/mice after boosting in
themagnitude and isotype skewing of the serum IgG responses, as
well as the total numbers of antigen-specific LLPCs and MBCs.
These results are consistent with the concept that IRF5 has a B-
cell-intrinsic function through its ability to modulate the plasma
cell maturation factor, Blimp-1 (43). While our data agree with
the trends identified in a prior study showing altered isotype skew-
ing in response to T-dependent or polyomavirus infection (29),
the magnitude of the phenotype after WNV infection was subtle.
Indeed, in a study by Fang et al., the antibody phenotypewasmore
pronounced in the Irf5/mice compared to Irf5cre/cre mice (29),
which could reflect the effect of the adventitious Dock2 mutation
on TH2-type effects (24).
In summary, our study shows that Irf5/ mice were more
vulnerable to lethal WNV infection. This phenotype was associ-
ated with defects in accumulation and activation of immune cells
in theDLN that likely reflected the loss of IRF5-dependent expres-
sion of proinflammatory cytokines and chemokines, with possible
subordinate effects on the type I IFN response. The altered DLN
response and deficits in the early antibody response correlated
with increasedWNV infection in the spleen and the bloodstream,
which resulted in higher peak titers in the brain and spinal cord.
Future studies with conditionally targeted mice are planned to
define the specific cell types that use IRF5 to shape LN responses
after viral infection or immunogen exposure. Given the wide
range of effects of loss-of-function and gain-of-function IRF5 al-
leles, an improved understanding of its specific functions in innate
and adaptive immunity could facilitate strategies that ameliorate
clinical outcomes in the context of viral infection, autoimmunity,
and neoplastic disease.
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